Search Results - "de la Rosa, Alan"

Successful use of rivaroxaban achieving therapeutic anti-factor xa levels in a morbidly obese patient with acute intermediate-high risk pulmonary embolism by Dah, Kingsley, Porres-Aguilar, Mateo, la Rosa, Alan De, Prakash, Swathi

“…Direct oral anticoagulants (DOACs) have become the standard of care for acute and long-term therapy for venous thromboembolism (VTE) due to their efficacy and…”
Get full text

Refractory Escherichia Coli Pneumonia: A Case Report by Khalafi, Seyed A, De La Rosa Vaquez, Alan, Dihowm, Fatma

“… pneumonia is a rare infection commonly presenting with a cavitary lesion. We report a case of a 44-year-old Hispanic male with comorbidities who was admitted…”
Get full text

S1632 Effect of Changes in Gastric Emptying and Low-Calorie Phenotype Tailored Diet on Weight Loss: Results From a 12-week Clinical Trial by Cifuentes, Lizeth, Ghusn, Wissam, Campos, Alejandro, Feris, Fauzi, Sacoto, Daniel, De la Rosa, Alan, Hurtado, Maria Daniela, Acosta, Andres

Get full text

Cardiovascular Risk and Diseases in Patients With and Without Leptin-Melanocortin Pathway Variants by Cifuentes, Lizeth, Campos, Alejandro, Sacoto, Daniel, Ghusn, Wissam, De la Rosa, Alan, Feris, Fauzi, McRae, Alison, Bublitz, Joshua T., Hurtado, Maria D., Olson, Janet, Acosta, Andres

“…To study differences in cardiovascular risk factors and diseases between patients with and without genetic variants in the leptin-melanocortin pathway. A…”
Get full text

S1648 Cardiovascular Disease Risk Improvement With Semaglutide in Patients With Obesity: A Multi-Centered Study by Ghusn, Wissam, Anazco, Diego, Fansa, Sima, Tama, Elif, De La Rosa, Alan, Nicolalde, Bryan, Cifuentes, Lizeth, Sacoto, Daniel, Campos, Alejandro, Feris, Fauzi, Gala, Khushboo, Calderon, Gerardo, Hashem, Anas, Hurtado, Maria Daniela, Acosta, Andres

“…[...]there is a significant need to prevent CVD by targeting excess adiposity in patients with obesity. Secondary outcomes included total body weight loss…”
Get full text

S1485 Semaglutide Outcomes in Non-Alcoholic Fatty Liver Disease: A Multi-Centered Real-World Study by Ghusn, Wissam, Fansa, Sima, Anazco, Diego, Tama, Elif, Nicolalde, Bryan, Gala, Khushboo, Cifuentes, Lizeth, De La Rosa, Alan, Sacoto, Daniel, Campos, Alejandro, Feris, Fauzi, Acosta, Andres

Get full text

A Case Report of Cytarabine-Induced Red Ear Syndrome by Botros, Monica, De La Rosa, Alan, Nadella, Sahithi, Chang, Aymara Y, Maharaj, Satish S

“…Cytarabine is an antimetabolite used in the treatment of acute myeloid leukemia which acts by inhibiting DNA synthesis and subsequently cell division. It works…”
Get full text

Association Between Food Intake and Gastrointestinal Symptoms in Patients With Obesity by Ghusn, Wissam, Cifuentes, Lizeth, Campos, Alejandro, Sacoto, Daniel, De La Rosa, Alan, Feris, Fauzi, Calderon, Gerardo, Gonzalez-Izundegui, Daniel, Stutzman, Jessica, Hurtado, Maria Daniela, Camilleri, Michael, Acosta, Andres

“…Hunger, satiation, postprandial satiety, and hedonic eating constitute key food intake parameters. We aim to study whether these symptoms are associated with…”
Get full text

Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity by Ghusn, Wissam, De la Rosa, Alan, Sacoto, Daniel, Cifuentes, Lizeth, Campos, Alejandro, Feris, Fauzi, Hurtado, Maria Daniela, Acosta, Andres

“…No retrospective cohort study has assessed the effectiveness of semaglutide at doses used in randomized clinical trials to treat obesity (ie, 1.7 and 2.4 mg)…”
Get full text

327 REGULATOR OF G-PROTEIN SIGNALING AS AN ENTEROENDOCRINE-SPECIFIC TARGET FOR OBESITY TREATMENT: ALTERED RGS9 IN ENTEROENDOCRINE CELLS IMPAIRS POSTPRANDIAL GLP-1 RESPONSE AND MODIFIES FOOD INTAKE IN MICE by Mcrae, Alison, Mangena, Nothando N., Feris, Fauzi, De la Rosa, Alan, Acosta, Andres

Get full text

Tu1920 SATIETY GLP-1 AND PYY HORMONES PLASMA CONCENTRATION IS NOT ASSOCIATED WITH M-RNA GUT MUCOSAL EXPRESSION IN DIET INDUCED OBESITY MICE by Mangena, Nothando N., Mcrae, Alison, Feris, Fauzi, De la Rosa, Alan, Acosta, Andres

Get full text

Achieving Therapeutic Anti-Xa Levels Using Rivaroxaban for Venous Thromboembolism in a Morbidly Obese Patient with a BMI >70 by Prakash, Swathi, Dah, Kingsley, Ghafouri, Sayed, De La Rosa, Alan, Porres-Aguilar, Mateo

Get full text

Real World Weight Loss Outcomes of Semaglutide in Patients With Overweight and Obesity by Ghusn, Wissam, De la Rosa, Alan, Cifuentes, Lizeth, Sacoto, Daniel, Campos, Alejandro, Feris, Fauzi, Hurtado, Maria Daniela, Acosta, Andres

“…Background: Obesity is a chronic and multifactorial disease, with a significant medical and economic burden. Semaglutide, a glucagon-like peptide-1 (GLP-1)…”
Get full text

Additive Effect of Obesity Phenotypes on Body Weight and Body Mass Index by Ghusn, Wissam, Cifuentes, Lizeth, Sacoto, Daniel, de la Rosa, Alan, Campos, Alejandro, Feris, Fauzi, Hurtado, Maria Daniela, Acosta, Andres

“…Background: Obesity originates from an imbalance between energy intake and expenditure. Changes in each of the energy intake components (satiation,…”
Get full text

Food Intake and Energy Expenditure Across the Lifespan of Adults with Obesity by Hurtado, Maria Daniela, Cifuentes, Lizeth, Campos, Alejandro, De la Rosa, Alan, Feris, Fauzi, Sacoto, Daniel, Ghusn, Wissam, Acosta, Andres

“…Background: The main regulators of body weight are food intake and energy expenditure. Hunger and satiation are important factors of food intake regulation,…”
Get full text

The association between previous use of anti‐obesity medication and semaglutide weight loss outcomes by Ghusn, Wissam, Fansa, Sima, Anazco, Diego, Tama, Elif, Cifuentes, Lizeth, Gala, Khushboo, De La Rosa, Alan, Sacoto, Daniel, Campos, Alejandro, Feris, Fauzi, Hurtado, Daniela, Acosta, Andres

“…Aims To compare weight loss outcomes between patients starting semaglutide who had previously been on another anti‐obesity medication (AOM) compared to those…”
Get full text

Polypill Strategy in Secondary Cardiovascular Prevention by De la Rosa, Alan, Arrington, Kedzie, Desai, Rohan, Acharya, Prakrati C.

“…Purpose of Review The polypill strategy, originally developed to improve medication adherence, has demonstrated efficacy in improving baseline systolic blood…”
Get full text

Mo1915 REAL-WORLD WEIGHT LOSS AND METABOLIC PARAMETERS OUTCOMES OF SEMAGLUTIDE: A 1-YEAR MULTI-SITE STUDY by Ghusn, Wissam, Fansa, Sima, Nicolalde, Bryan, De la Rosa, Alan, Cifuentes, Lizeth, Sacoto, Daniel, Anazco, Diego, Gala, Khushboo, Campos, Alejandro, Feris, Fauzi, Hurtado, Maria D., Acosta, Andres

Get full text

Mo1916 SEMAGLUTIDE WEIGHT LOSS AND METABOLIC PARAMETERS OUTCOMES IN PATIENTS AFTER BARIATRIC SURGERIES: A 1-YEAR MULTI-CENTERED STUDY by Ghusn, Wissam, Fansa, Sima, Nicolalde, Bryan, De la Rosa, Alan, Cifuentes, Lizeth, Sacoto, Daniel, Anazco, Diego, Gala, Khushboo, Hurtado, Maria D., Acosta, Andres

Get full text

Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study by Ghusn, Wissam, Fansa, Sima, Anazco, Diego, Tama, Elif, Nicolalde, Bryan, Gala, Khushboo, De la Rosa, Alan, Sacoto, Daniel, Cifuentes, Lizeth, Campos, Alejandro, Feres, Fauzi, Hurtado, Maria Daniela, Acosta, Andres

“…Background/Objective There are limited real-world studies assessing semaglutide weight loss and associated comorbidity and metabolic outcomes over periods ≥ 6…”
Get full text